Pancreatic Cancer Research

ResearcherKagoshima UniversityNo recent work listed

Qiang Ding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6226-869X; OpenAlex author ID A5085617980. Sources: OpenAlex.

Their work

Papers
13 (first author 7, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2012: 5 papers · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers

Papers 13

  1. miR-30 family promotes migratory and invasive abilities in CD133(+) pancreatic cancer stem-like cells. First author DOI 10.1007/s13577-016-0137-7↗
  2. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition. Co-author DOI 10.1186/s12943-016-0534-2↗
  3. CD133 Modulate HIF-1α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells. First author DOI 10.3390/ijms17071025↗
  4. Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells. First author DOI 10.1007/s13577-015-0117-3↗
  5. S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Last author DOI 10.1038/srep08453↗
  6. Hypoxia inducible factor-1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study. First author DOI 10.1002/jhbp.6↗
  7. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Co-author DOI 10.1186/1476-4598-13-15↗
  8. mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. First author DOI 10.1038/srep03230↗
  9. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. Co-author DOI 10.1002/jso.23020↗
  10. Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy. First author DOI 10.1007/s00534-012-0547-1↗
  11. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic c… Co-author DOI 10.1007/s13577-011-0037-9↗
  12. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. First author DOI 10.1111/j.1349-7006.2012.02235.x↗
  13. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2263-0↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sonshin Takao · 12 shared papers, 2012–2016 · strength 0.56
  2. Yumi Miyazaki · 8 shared papers, 2012–2016 · strength 0.41
  3. Koichiro Tsukasa · 6 shared papers, 2013–2016 · strength 0.35
  4. Shyuichiro Matsubara · 6 shared papers, 2012–2016 · strength 0.30
  5. Shoji Natsugoe · 7 shared papers, 2012–2016 · strength 0.29
  6. Koki Maeda · 5 shared papers, 2012–2016 · strength 0.17
  7. Tomomi Hayashi · 3 shared papers, 2012–2016 · strength 0.12
  8. Kosei Maemura · 3 shared papers, 2012–2014 · strength 0.10
  9. Yuko Mataki · 3 shared papers, 2012–2014 · strength 0.10
  10. Hiroyuki Shinchi · 2 shared papers, 2012–2016 · strength 0.08
  11. Hiroshi Kurahara · 2 shared papers, 2012 · strength 0.06
  12. Yoichiro Matsuo · 1 shared paper, 2014 · strength 0.04
  13. Donald J Buchsbaum · 1 shared paper, 2015 · strength 0.04
  14. Pulin Che · 1 shared paper, 2015 · strength 0.04
  15. John D. Christein · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.